Company Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases.
Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B.
The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
| Country | NL |
| IPO Date | Feb 5, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 480 |
| CEO | Christian Klemt |
Contact Details
Address: Paasheuvelweg 25a Amsterdam, NL | |
| Website | https://www.uniqure.com |
Stock Details
| Ticker Symbol | QURE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001590560 |
| CUSIP Number | N90064101 |
| ISIN Number | NL0010696654 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew Craig Kapusta CPA | Chief Executive Officer & Executive Director |
| Christian Klemt | Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site |
| Dr. Amin Abujoub Ph.D. | Chief Technical Operations |
| Dr. Jeannette Potts J.D., Ph.D. | Chief Legal & Compliance Officer and Corporate Secretary |
| Dr. Tamara Tugal Ph.D., MBA | Business Development Director |
| Dr. Walid Abi-Saab M.D. | Chief Medical Officer |
| Eileen Sawyer | Vice President of Global Medical Affairs |
| Erin Boyer | Chief People & Culture Officer |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany |
| Richard Porter Ph.D. | Chief Business & Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 12, 2024 | 4 | Filing |
| Dec 10, 2024 | 4 | Filing |
| Dec 10, 2024 | 4 | Filing |
| Dec 10, 2024 | 8-K | Current Report |
| Nov 21, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 05, 2024 | 10-Q | Quarterly Report |
| Nov 05, 2024 | 8-K | Current Report |